Non-alcoholic fatty liver disease and risk of cardiovascular disease

被引:166
|
作者
Lonardo, Amedeo [1 ,2 ,3 ]
Sookoian, Silvia [4 ]
Pirola, Carlos J. [5 ]
Targher, Giovanni
机构
[1] Azienda USL, NOCSAE, Dept Biomed Metab & Neural Sci, Outpatient Liver Clin, Modena, Italy
[2] Azienda USL, NOCSAE, Dept Biomed Metab & Neural Sci, Div Internal Med, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Buenos Aires, Nat Sci & Tech Res Council CONICET, Inst Med Res A Lanari IDIM, Dept Clin & Mol Hepatol, Buenos Aires, DF, Argentina
[5] Univ Buenos Aires, Nat Sci & Tech Res Council CONICET, Inst Med Res A Lanari IDIM, Dept Mol Genet & Biol Complex Dis, Buenos Aires, DF, Argentina
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2016年 / 65卷 / 08期
关键词
NAFLD; CVD; Cardiovascular risk; GAMMA-GLUTAMYL-TRANSFERASE; CORONARY-HEART-DISEASE; SUPERFAMILY MEMBER 2; TERM-FOLLOW-UP; HEPATIC STEATOSIS; PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; DIABETES-MELLITUS; CONFERS SUSCEPTIBILITY; ATRIAL-FIBRILLATION;
D O I
10.1016/j.metabol.2015.09.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. During the past decade, it has also become increasingly evident that NAFLD is a multisystem disease that affects many extra-hepatic organ systems, including the heart and the vascular system. In this updated clinical review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong association of NAFLD with cardiovascular diseases (CVDs) and other functional and structural myocardial abnormalities. We also discuss some recently published data that correlate NAFLD due to specific genetic polymorphisms with the risk of CVDs. Finally, we briefly examine the assessment tools for estimating the global CVD risk in patients with NAFLD as well as the conventional and the more innovative pharmacological approaches for the treatment of CVD risk in this group of patients. (C) 2016 Elsevier Inc. All rights reserved.
引用
下载
收藏
页码:1136 / 1150
页数:15
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease and the risk of dementia
    Zhou, Zhiyong
    Niu, Xiaoqiang
    Cao, Jiaqing
    Li, Huizi
    LIVER INTERNATIONAL, 2022, 42 (08) : 1912 - 1913
  • [42] NON-ALCOHOLIC FATTY LIVER DISEASE IS A PREDICTOR OF CARDIOVASCULAR DISEASES
    Stepanova, M.
    Younossi, Z. M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S11 - S11
  • [43] CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE COMPARED TO ALCOHOLIC LIVER DISEASE.
    Abe, Temidayo
    Ajose, Taiwo A.
    Ajose, Afolarin
    Abe, Tolulope
    Patel, Parth
    Sobukonla, Timothy
    Surapaneni, Phani Keerthi
    GASTROENTEROLOGY, 2020, 158 (06) : S346 - S347
  • [44] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [45] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [46] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [47] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [48] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    LANCET, 2021, 397 (10290): : 2212 - 2224
  • [49] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [50] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    BMC MEDICINE, 2017, 15